Clinical Trial Update: The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the combination of Sintilimab with doxorubicin/Ifosfamide as first-line therapy for select metastatic/unresectable soft tissue sarco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• IFOSFAMIDE (IFOSFAMIDE)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Sarcoma, Soft Tissue | Phase 2 | Status: UNKNOWN